Phase 2 Recurrent B Acute Lymphoblastic Leukemia Clinical Trials
4 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–4 of 4 trials
Recruiting
Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
Recurrent B Acute Lymphoblastic LeukemiaB Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeRefractory B Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)84 enrolled274 locationsNCT03739814
Recruiting
Phase 2
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Recurrent B Acute Lymphoblastic LeukemiaRefractory B Acute Lymphoblastic LeukemiaRecurrent B Lymphoblastic Lymphoma+1 more
Children's Oncology Group80 enrolled157 locationsNCT02981628
Recruiting
Phase 1Phase 2
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
Recurrent Burkitt LymphomaRefractory Burkitt LymphomaB Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1+6 more
M.D. Anderson Cancer Center276 enrolled1 locationNCT01371630
Recruiting
Phase 2
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Recurrent B Acute Lymphoblastic LeukemiaDown Syndrome
National Cancer Institute (NCI)461 enrolled215 locationsNCT04546399